Huddersfield researchers demonstrate how coronavirus activates the brain's immune response

NewsGuard 100/100 Score

Huddersfield researchers were among the first to demonstrate how the induction of brain inflammation accounts for neurological damage in COVID19 patients and now, their findings have been published in a peer-reviewed medical journal.

The study, published in the journal Molecular Neurobiology led by the University of Huddersfield's Dr. Mayo Olajide, describes how the spike protein used by the coronavirus to enter human cells can have a similar effect on the brain's immune cells as it does with the rest of the body.

Dr Olajide, who's previous research discovered how the onset of Alzheimer's disease can be slowed and some of its symptoms curbed by a natural compound that is found in pomegranate, conducted the potential impact of the Spike Glycoprotein S1 using immune cell lines obtained from mice and is now applying for funding to develop the research further using brain cells from humans.

Following our hypothesis, we are now questioning when the coronavirus has affected the brain, could this pose a risk for neurodegenerative disorders further down the line, like Alzheimer's or Parkinson's?"

Dr. Mayo Olajide, University of Huddersfield

How the coronavirus activate the brain's own immune response

According to Dr Olajide, whilst other research demonstrated the mechanism of why the virus was able to gain access into the brain through the nose, theirs was among the first to demonstrate how the coronavirus activated the brain's own immune response.

"It may not be multiplying in the brain, but when it gets into the brain, it can actually induce immune responses and this explains some of the trends people have reported when they have been infected such as continued brain fog and memory loss," he said.

Dr Olajide believes if adequate funding can be achieved the research could prove significant.

"The thing with COVID research is so many researchers speculate but less actually carry out the experiments needed to prove their research because it takes such a long time to complete."

Dr Olajide is a Reader within the University's Department of Pharmacy in the School of Applied Sciences. His academic career includes a post as a Humboldt Postdoctoral Research Fellow at the Centre for Drug Research at the University of Munich. His PhD was awarded from the University of Ibadan in his native Nigeria, after an investigation of the anti-inflammatory properties of natural products.

Source:
Journal reference:

Olajide, O.A., et al. (2022) SARS-CoV-2 Spike Glycoprotein S1 Induces Neuroinflammation in BV-2 Microglia. Molecular Neurobiology. doi.org/10.1007/s12035-021-02593-6.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds dysfunction of key brain systems in people with psychosis